|
|
||||||||
letter |
aInstitut für Molekulare Tierzucht und Biotechnologie, Genzentrum der LMU München, Munich, Germany;
bKlinische Kooperationsgruppe Hämatopoetische Zelltransplantation, GSF-Nationales Forschungszentrum für Umwelt und Gesundheit GmbH, und Medizinische Klinik III der LMU München, Munich, Germany;
cChirurgische und Gynäkologische Kleintierklinik, Tierärztliche Fakultät der LMU München, Munich, Germany
Key Words. Embryonic stem cells • In vitro differentiation • Dog • Hematology
Correspondence: Marlon R. Schneider, D.V.M., Institute of Molecular Animal Breeding and Biotechnology, Gene Center, University of Munich, Feodor-Lynen-Str. 25, 81377 Munich, Germany. Telephone: +49 89 218076815, Fax: +49 89 218076849, e-mail: schnder{at}lmb.uni-muenchen.de
Received June 10, 2006;
accepted for publication March 29, 2007.
Pluripotent embryonic stem (ES) cells, which are available in mouse [1, 2] and human [3], are permanent cell lines that can differentiate into cell types of all three germ layers. Therefore, ES cells have a remarkable potential for both basic research and clinical applications toward replacement of degenerated or malignant cells. From the perspective of hematology, where stem cell therapies are most advanced, ES cells have a number of advantages over conventional sources of transplantable material. They can be expanded indefinitely in vitro, and, more importantly, they can be obtained from a bank representing major haplotype combinations [4] or may even be derived by reprogramming somatic cells from individual patients. Proof of principle for this "therapeutic cloning" concept has been provided in the mouse [5]; however, translation of ES cell-based therapeutic strategies to clinical application requires larger animal models for predictive efficacy and safety studies.
The dog has been used for preclinical studies of stem cell transplantation, and many techniques have been derived from canine studies [6]. Furthermore, techniques applicable to canine cells and dogs can be applied to man, taking into account known biologic properties of the dog [7]. Since the dog is the ideal preclinical model for testing new therapies for many human diseases, the availability of canine embryo-derived stem cells for in vitro differentiation studies will be of great value for the development of new therapies, especially in hematology. Moreover, nuclear transfer from canine somatic cells is possible [8], providing the opportunity to evaluate the concept of "therapeutic cloning" in a clinically relevant animal model.
In a recent report, Hatoya and colleagues [9] describe the isolation of two ES-like cell lines from canine blastocysts. The cell lines were shown to exhibit characteristic ES-like morphology and expression of pluripotency markers. Importantly, the cells formed embryoid bodies in suspension culture, which differentiated upon adhesive culture into various cell types, including neuron-like, epithelium-like, fibroblast-like, melanocyte-like, and myocardium-like cells, demonstrating that these cells are indeed pluripotent. Unfortunately, it was not possible to maintain the undifferentiated phenotype of the cell lines beyond passage 8.
We have performed similar studies that confirm the possibility of establishing canine embryo-derived cell lines and, more importantly, demonstrate for the first time that these cells can be differentiated into hematopoietic stem cells. Eight blastocysts were obtained from a Golden Retriever bitch by flushing the uterine horns after ovariohysterectomy. After mechanical removal of the embryonic coats, the blastocysts were cultured individually on mitotically-inactivated mouse embryonic fibroblasts in 48-well plates (for further details, see supplemental online Methods). From one blastocyst, colonies exhibiting typical ES-like morphology (Fig. 1A) were obtained. At this stage, the cells could be maintained independent of mouse feeder cells but formed autologous feeders as previously described for human ES cells [10]. Cytogenetic analysis confirmed the canine origin of the cells, which contained a Y chromosome (Fig. 1B). The ES-like cells exhibited alkaline phosphatase activity (Fig. 1C) and expressed NANOG, OCT4, and SOX2, the most important pluripotency-associated transcription factors for mouse and human ES cells (Fig. 1D). Sequencing confirmed that the obtained polymerase chain reaction (PCR) products correspond to canine sequences. Furthermore, in agreement with the report by Hatoya et al. [9], the canine ES-like cells showed expression of SSEA-1 but were negative for SSEA-4 (data not shown).
|
| DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. R. Schneider, E. Wolf, J. Braun, H.-J. Kolb, and H. Adler Canine embryo-derived stem cells and models for human diseases Hum. Mol. Genet., April 15, 2008; 17(R1): R42 - R47. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hayes, S. R. Fagerlie, A. Ramakrishnan, S. Baran, M. Harkey, L. Graf, M. Bar, A. Bendoraite, M. Tewari, and B. Torok-Storb Derivation, Characterization, and In Vitro Differentiation of Canine Embryonic Stem Cells Stem Cells, February 1, 2008; 26(2): 465 - 473. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |